Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech’s projections.
Late Wednesday, Dyne priced its offering of about 12.3 million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3 million shares in the range of $16 to $18 per share. Those shares are expected to begin trading on the Nasdaq Thursday under the stock symbol “DYN.”
Dyne is developing drugs that employ a proprietary technology intended to overcome one of the hurdles to treating muscular disorders: getting enough medicine into muscle… Read more »
UNDERWRITERS AND PARTNERS